TY - JOUR
T1 - Venetoclax in acute myeloid leukemia–current and future directions
AU - Lachowiez, Curtis
AU - DiNardo, Courtney D.
AU - Konopleva, Marina
N1 - Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/5/11
Y1 - 2020/5/11
N2 - B-cell leukemia/lymphoma-2 (BCL-2) inhibition with the targeted oral agent venetoclax (ABT-199) has reshaped the treatment landscape for multiple hematological malignancies. Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has led to improved outcomes in acute myeloid leukemia (AML) and represents a new standard of care for frontline AML treatment in older patients or those unfit for intensive chemotherapy. Combinations of venetoclax with standard induction therapy or targeted agents such as FLT-3 inhibitors and IDH inhibitors are leading to improved clinical outcomes, representing major advancements in a field that has been without significant changes in treatments for the last 30 years. This review provides biological and clinical rationale for current venetoclax based treatments in AML, addresses common adverse events encountered with venetoclax based therapy, and explores emerging clinical data regarding combinations of novel targeted therapeutics used in conjunction with venetoclax for the treatment of AML.
AB - B-cell leukemia/lymphoma-2 (BCL-2) inhibition with the targeted oral agent venetoclax (ABT-199) has reshaped the treatment landscape for multiple hematological malignancies. Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has led to improved outcomes in acute myeloid leukemia (AML) and represents a new standard of care for frontline AML treatment in older patients or those unfit for intensive chemotherapy. Combinations of venetoclax with standard induction therapy or targeted agents such as FLT-3 inhibitors and IDH inhibitors are leading to improved clinical outcomes, representing major advancements in a field that has been without significant changes in treatments for the last 30 years. This review provides biological and clinical rationale for current venetoclax based treatments in AML, addresses common adverse events encountered with venetoclax based therapy, and explores emerging clinical data regarding combinations of novel targeted therapeutics used in conjunction with venetoclax for the treatment of AML.
KW - Myeloid leukemias and dysplasias
KW - cell cycle and apoptosis changes
KW - pharmacotherapeutics
KW - signaling therapies
UR - http://www.scopus.com/inward/record.url?scp=85079449425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079449425&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1719098
DO - 10.1080/10428194.2020.1719098
M3 - Article
C2 - 32031033
AN - SCOPUS:85079449425
SN - 1042-8194
VL - 61
SP - 1313
EP - 1322
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -